JAAD Case Reports · 2023 · 20 citations · 2 references
MedicineDermatologyPharmacotherapyAutoimmunityImmunopathologyImmunopharmacologyAutoimmune Skin DiseasesImmunosuppressionMonoclonal Antibody TherapySystemic Lupus ErythematosusTreatmentBiologic Anti-inflammatory TherapiesSubacute Cutaneous Lupus ErythematosusSystemic Immunosuppressive TherapyTherapeutic Corticosteroids
Cutaneous lupus erythematosus (CLE) is an autoimmune disorder involving a broad range of dermatologic manifestations that can occur in the presence or absence of associated systemic lupus erythematosus (SLE).1 Subacute cutaneous lupus erythematosus (SCLE) is one of 3 main subtypes of CLE that are differentiated according to histopathology and clinical findings and can be triggered by endogenous or exogenous factors.2 Treatment for SCLE traditionally involved a combination of preventive strategies, topical therapies (such as corticosteroids or calcineurin inhibitors), and systemic therapies for widespread disease, including oral antimalarials, systemic corticosteroids, immunosuppressants, and biologic therapies.
2
Eric F. Morand, Marilyn C. Pike, Joan T. Merrill et al. · Arthritis & Rheumatology · 2022 · 248 citations · Full text
Inbal Braunstein, R Klein, Joyce Okawa et al. · British Journal of Dermatology · 2012 · 178 citations